{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:41:32Z","timestamp":1788489692692,"version":"build-2803163510"},"reference-count":9,"publisher":"SAABRON PRESS","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.46989\/001c.158751","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:25:31Z","timestamp":1773332731000},"source":"Crossref","is-referenced-by-count":1,"title":["MajesTEC-3: Redefining what\u2019s possible in multiple myeloma"],"prefix":"10.46989","volume":"8","author":[{"given":"Samer","family":"Al Hadidi","sequence":"first","affiliation":[{"name":"Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Gaballa","sequence":"additional","affiliation":[{"name":"Department of Lymphoma - Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"8","key":"ref1","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1001\/jamaoncol.2025.1394","article-title":"Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols: A Secondary Analysis of 3 Clinical Trials","volume":"11","author":"S. Al Hadidi","year":"2025","journal-title":"JAMA Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma","author":"L. J. Costa","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"ref3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-025-01282-0","article-title":"Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma","volume":"15","author":"M. Mohan","year":"2025","journal-title":"Blood Cancer J"},{"issue":"13","key":"ref4","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"F. Mazahreh","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"ref5","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"D. M. Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"issue":"suppl 1","key":"ref6","doi-asserted-by":"publisher","first-page":"5814","DOI":"10.1182\/blood-2025-5814","article-title":"Interim analysis of LimiTEC, a prospective trial of limited-duration teclistamab for relapsed\/refractory multiple myeloma","volume":"146","author":"B. Razzo","year":"2025","journal-title":"Blood"},{"issue":"4","key":"ref7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"P. Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"ref8","article-title":"TECVAYLI\u00ae monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide","author":"Johnson & Johnson","year":"2026"},{"issue":"8","key":"ref9","doi-asserted-by":"publisher","first-page":"e2228877","DOI":"10.1001\/jamanetworkopen.2022.28877","article-title":"Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma","volume":"5","author":"R. Alqazaqi","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/158751-majestec-3-redefining-what-s-possible-in-multiple-myeloma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:25:31Z","timestamp":1773332731000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/158751-majestec-3-redefining-what-s-possible-in-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.158751","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}